Georgia CTSA COVID-19 Response
Georgia CTSA is taking an active role in monitoring the COVID-19 pandemic and sharing important news updates. We are continuously collecting and sharing news of how our trainees, scholars, investigators, faculty, and staff are responding to the COVID-19 virus. Check-in here to learn more about what we are doing in support of the COVID-19 response and for more information on resources available to you.
Feature StoriesGeorgia CTSA Leaders to Begin Phase 1 Validation for National COVID-19 Tests
Two of Georgia CTSA's leaders head up the NIBIB-funded Atlanta Center Microsystems Engineered Point of Care Technologies (ACME POCT) which has been selected by the NIH, along with their institutions - Emory, Georgia Tech, and Children’s Healthcare of Atlanta - to test and validate some of the most promising technologies for COVID-19 diagnostic testing.Former Georgia CTSA KL2 Scholar Helps Lead COVID-19 Research Efforts
As an accomplished research physician-scientist with several NIH R01 grants as Principal Investigator, Colleen Kelley MD, MPH, Associate Professor, Emory University School of Medicine, Division of Infectious Diseases, and Georgia Clinical & Translational Science Alliance (Georgia CTSA) former KL2 Scholar is actively involved in several research efforts around COVID-19 including ongoing clinical trials and related research activities.
Christina Gavegnano, PhD, Assistant Professor, Emory University School of Medicine, and Georgia Clinical & Translational Science Alliance (Georgia CTSA) Certificate Program in Translational Research (CPTR) graduate, has been working with Baricitinib for the indication of HIV and shares the internationally-issued patent for use for viral infections. Baricitinib has been selected by the National Institutes of Health (NIH) for a multi-country phase 3 study for COVID-19 treatment.
Marybeth Sexton, MD, MSc, Assistant Professor, Emory University School of Medicine, member of the Serious Communicable Disease Unit team at Emory University Hospital and Georgia Clinical & Translational Science Alliance (Georgia CTSA) Master in Science in Clinical Research (MSCR) graduate, has been actively sharing COVID-19 prevention and protective strategies to limit the spread of COVID-19. Her current focus is on communicating the importance of social distancing during the pandemic.
Sara Auld, MD, MSc, Assistant Professor, Emory University School of Medicine and Rollins School of Public Health, and Georgia Clinical & Translational Science Alliance (Georgia CTSA) Master in Science in Clinical Research (MSCR) graduate, has helped her team develop best practices and guidelines for ICU patients at Emory University Hospital Midtown who have COVID-19.
Paulina Rebolledo, MD, MSc, Assistant Professor, Emory University School of Medicine, Division of Infectious Diseases, Rollins School of Public Health, Hubert Department of Global Health and Georgia Clinical & Translational Science Alliance (Georgia CTSA) Master in Science in Clinical Research (MSCR) graduate, has worked with her team to scale up an in-house COVID-19 diagnostic test at Grady Memorial Hospital.
Annette Esper, MD, MSc, Associate Professor, Emory University School of Medicine, Division of Pulmonary and Critical Care Medicine, and Georgia Clinical & Translational Science Alliance (Georgia CTSA) Master in Science in Clinical Research (MSCR) graduate, is engaged with her team in Grady’s ICU in the ongoing battle against COVID-19. The team restructured their current intensive care units and deployment of those units. Since there are multiple ICUs at Grady, the team cohorted the COVID patients and designated a specific ICU a COVID ICU.
Jeffrey Collins, MD, MSc, Assistant Professor, and Russell Kempker, MD, MSc, Associate Professor, Emory University School of Medicine, Division of Infectious Diseases, NIH-funded physician-scientists, and Georgia Clinical & Translational Science Alliance (Georgia CTSA) Master in Science in Clinical Research (MSCR) graduates, are on the front lines of the battle against COVID-19. Collins and Kempker were both on Infectious Diseases clinical service at Grady Hospital when the SARS-CoV2 virus came to Atlanta and diagnosed the first patients seen at Grady with COVID-19.
Emory's first coronavirus patient began receiving infusion therapy as a result of Georgia CTSA's assistance in coordinating the approvals needed within 48 hours. Georgia CTSA's Navigator Team utilized the new Standard Operating Procedure (SOP) for its Rapid Response Team service to obtain fast-track approvals across the Emory system.
Georgia CTSA Clinical Research Centers (GCRCs) Director Colleen Kraft, MD, MSc, has been named to Georgia Governor Brian Kemp's Coronavirus Task Force. The 18-member task force of health, airport, school and emergency preparedness officials has been asked to identify the best way to prevent the spread of the coronavirus in Georgia.
Funding OpportunitiesNew R01, R21 Pair of COVID-19 Emergency FOAs – Rolling Submission
NIAID recently issued two new funding opportunity announcements (FOAs) as part of our continuing effort to support research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). The two FOAs are ideal for applicants proposing new coronavirus-related research projects. The scope and nature of your proposed research project should guide your decision whether to apply through the R01 or R21 FOA. They feature rolling submission, meaning you can apply as soon as it is ready and NIAID will review it in an expedited fashion.NIH POCTRN: Innovative Technologies to Increase U.S. Capacity for COVID-19 Testing – Rolling Submission
The National Institute of Biomedical Imaging and Bioengineering (NIBIB) is urgently soliciting proposals and can provide up to $500M across multiple projects to rapidly produce innovative SARS-CoV-2 diagnostic tests that will assist the public’s safe return to normal activities. Rapid Acceleration of Diagnostics (RADx), is a fast-track technology development program that leverages the National Institutes of Health (NIH) Point-of-Care Technology Research Network (POCTRN). NIBIB will support the full range of product development including commercialization and product distribution.
Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (NOT-RM-20-015) – Due April 15 through June 19
The NIH Common Fund received $30 Million from the Coronavirus Aid, Relief, and Economic Security (CARES) Act, 2020 to prevent, prepare for, and respond to coronavirus, domestically or internationally. OSC issued this Notice of Special Interest (NOSI), an opportunity for emergency competitive revisions to Common Fund grants and cooperative agreements to support innovative, impactful research on COVID-19 or SARS-CoV-2 in any area of research including behavioral/social science, health disparities, and novel therapeutics that fits within the mission of an emergency response to provide critical expertise, resources or activities. OSC plans to use a portion of the CARES Act funds to support 10-20 high-impact, one-year, one-time, competitive revisions for Common Fund awards only in Fiscal year 2020. OSC is planning new funding opportunities to support new research projects in these areas beginning in Fiscal Year 2021. OSC staff will host a technical assistance webinar to answer applicant questions on May 6, 2020. Applications will be accepted on a rolling basis from April 15, 2020 through June 19, 2020, by 5:00 PM local time of the applicant organization.
National Center for Advancing Translational Sciences (NCATS) is issuing this Notice of Special Interest to highlight the urgent need for research on the 2019 novel coronavirus and the disease it causes. NCATS is particularly interested in projects that repurpose existing drugs or biologics (existing therapeutics) that have already begun or completed a Phase I clinical trial.
Pfizer Global Medical Grants support patient-focused programs that help patients and providers address the heightened medical and educational needs of patients with primary immunodeficiency during this pandemic. Priority will be awarded to projects that leverage the utilization of innovative technology platforms for distant learning to reach the intended audience with a focus on patient outreach, medical support and telework.
With information and funding opportunities quickly evolving during this pandemic, we want to make sure our NCATS Consortium has the most up-to-date and readily available information. You can find the latest opportunities that NCATS is participating in by following this link.
To support our faculty in the university initiative to estimate the impact on your sponsored research projects from COVID-19, the Office of Research Administration (ORA) has developed a list of FAQs. While the list will likely address many of your questions, please continue to work with your respective RAS units and staff who are available to help you estimate this impact and answer additional questions.
If you are a scientist at an academic institution currently working on a COVID-19 related project and in need of funding, we invite you to apply for a Fast Grant. Fast Grants are $10k to $500k and decisions are made in under 48 hours. If we approve the grant, you'll receive payment as quickly as your university can receive it.
As the COVID-19 situation continues to develop, it’s critically important that researchers, who are learning about the virus and pursuing science-based solutions to the global coronavirus pandemic, can find the funding they need. With this in mind, GrantForward is proud to provide free access to a list of funding opportunities in the area of COVID-19. The list of available coronavirus-related funding calls and other support for researchers, non-profit organizations and commercial organizations, with all relevant information, will be updated on a daily basis.
The NIH is devoting significant resources to COVID-19. In addition to dedicating regularly appropriated funds, to date NIH has received emergency funding for COVID-19-related activities in two supplemental bills. To get funding as quickly as possible to the research community, we are using Urgent and Emergency competing revisions and administrative supplements to existing grant awards. Learn more about what is available today.
Research ResourcesNCATS Web Content on The National COVID Cohort Collaborative (N3C)
NCATS web content on the National COVID Cohort Collaborative (N3C) is now available including links to program resources, related funding opportunities, and frequently asked questions.National COVID Cohort Collaborative (N3C)
The National Center for Data to Health and NCATS are leading the creation of a national, centralized, secure portal for COVID-19 clinical data. The cloud-based collaborative portal will allow for the development of machine learning and other informatics tools that require a large row-level dataset and will be overseen by a data access committee. This portal will provide additional assets needed to rapidly develop the analytics that clinical centers and physicians need now.COVID-19 Collaboration Platform
The COVID-19 Collaboration Platform brings unassociated research teams working on the same clinical research questions together to share protocols, data, and evidence. COVID-19 Collaboration Platform offers support managing collaborations, including expedited and prioritized help from the Trial Innovation Network and SMART IRB to form multi-site trials; expert statistical advice for aggregated analyses, and free data storage and anonymization through vivli.org.
For up-to-date NIH COVID-19 information, including: Informational Videos; Proposal Submission & Award Management Resources; Human Subjects & Clinical Trials Guidance; Animal Welfare; Frequently Asked Questions regarding flexibilities for grantees and; Funding Opportunities, please visit the link.
In response to new CDC guidance, the Division of Animal Resources will provide one face mask per person/week, one disposable yellow gown per person/week per room, and a storage container. This practice aligns with Emory Healthcare and aims to protect staff while conserving personal protective equipment (PPE). View the link below to learn more details on the revised PPE guidance.
Many Emory investigators are pursuing essential and critical research projects focused on the COVID-19 pandemic. If you have plans to collect or are currently collecting samples from COVID-19 patients, please respond with a brief description of your work and the type of sample (DNA, serum, PBMCs) you need. Providing essential platforms to support COVID-19 research is a high priority. Requests for new equipment to directly support COVID-19 research are being collected via email. Please send an email to Mike Zwick at email@example.com.
We are a community of medical professionals, life scientists and data scientists on a quest to defeat COVID-19. To pitch in, join our discourse!
The COVID-19 HPC Consortium encompasses computing capabilities from some of the most powerful and advanced computers in the world. We hope to empower researchers around the world to accelerate understanding of the COVID-19 virus and the development of treatments and vaccines to help address infections. Consortium members manage a range of computing capabilities that span from small clusters to some of the very largest supercomputers in the world. Learn more about how to request access to resources of the COVID-19 HPC Consortium.
Special Webinar Events
Tuesday, June 2nd, 4:00 pm - 5:00 pm
Tuesday, June 16th, 12:00 pm - 1:00 pm
Previous Workshops and Webinar Sessions:
Blue Sky Groups
"Brain Health and COVID-19"
Watch on YouTube:
Team Science Workshops
"Community Engagement in the Era of COVID-19: Opportunities, Challenges, and Lessons Being Learned"
"Managing Lab Trainees During this Unprecedented Time"
"Managing Clinical Trainees During This Time"
"Ramping Down Clinical Trials"